Foundayo vs Wegovy: Head-to-Head Evidence Comparison

This head-to-head evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Foundayo (orforglipron) and Wegovy (semaglutide) are both GLP-1 receptor agonists FDA-approved for chronic weight management, but they are different molecules with different delivery routes, different FDA labels, and different cardiovascular evidence. Wegovy produces modestly more weight loss at maximum dose. Foundayo is the first oral GLP-1 ever approved for obesity. This article walks through the head-to-head evidence with the trial and FDA-label citations behind every claim.

Two different molecules at the same receptor

Both drugs target the glucagon-like peptide-1 receptor (GLP-1R) on pancreatic beta cells, vagal afferents, and hypothalamic appetite centers. The receptor target is the same. The molecules that hit it are not.

Wegovy is semaglutide, a 31-amino-acid synthetic peptide analogue of the natural GLP-1 hormone, with a C18 fatty-diacid side chain that enables binding to circulating albumin and a once-weekly half-life. Semaglutide is a peptide; it must be delivered by subcutaneous injection because gastrointestinal proteases would degrade it if swallowed. Manufactured by Novo Nordisk.

Foundayo is orforglipron, a small-molecule non-peptide allosteric GLP-1 receptor agonist with an oral bioavailability profile that allows once-daily tablet administration. Because it is not a peptide, gastrointestinal digestion does not destroy it, and it can be taken any time of day with or without food, with no water restrictions per the FDA prescribing information^[7]. Manufactured by Eli Lilly.

Both molecules are monoagonists — they bind only the GLP-1 receptor. Neither is a dual-agonist like tirzepatide (Zepbound, Mounjaro), which activates both GLP-1 and GIP receptors. For the wider drug-class comparison see the full GLP-1 medication reference.

FDA indications and dose ladders side-by-side

Mean total body weight loss: ATTAIN-1 vs STEP-1

Neither Foundayo nor Wegovy has been tested against the other in a single randomized head-to-head trial. The closest cross-comparison available is the matched-population indirect comparison between the Foundayo pivotal trial (ATTAIN-1) and the Wegovy pivotal trial (STEP-1), both of which enrolled adults with obesity or overweight without type 2 diabetes.

ATTAIN-1: the Foundayo pivotal weight-loss trial

ATTAIN-1 (Wharton et al., NEJM 2025) randomized adults with obesity without type 2 diabetes to orforglipron at 6 mg, 12 mg, or 36 mg daily, or placebo, with a lifestyle-intervention background, for 72 weeks^[1]. The trial tested 6, 12, and 36 mg arms; the FDA-approved labeled max dose published in the Foundayo US Prescribing Information Section 14 is 17.2 mg daily, which produces approximately −11.1% mean body weight at 72 weeks in the ATTAIN-1 population^[7]. The 36 mg trial arm (above the labeled max) reported approximately 11-12% mean reduction in the published manuscript. The number patients will see in real-world prescribing is the labeled-dose 17.2 mg figure.

STEP-1: the Wegovy pivotal weight-loss trial

STEP-1 (Wilding et al., NEJM 2021) randomized 1,961 adults with overweight or obesity without diabetes to semaglutide 2.4 mg weekly or placebo, with a lifestyle-intervention background, for 68 weeks. Mean body-weight reduction was −14.9% on semaglutide 2.4 mg vs −2.4% on placebo (treatment-regimen estimand). Approximately 32% of semaglutide-treated patients reached at least 20% body-weight reduction^[4].

The indirect-comparison caveat

ATTAIN-1 and STEP-1 are not directly comparable because they enrolled different patient populations (different baseline weights, slightly different BMI inclusion thresholds, different ethnic and geographic distributions), used different lifestyle-intervention backgrounds, and reported at different timepoints (72 vs 68 weeks). The 3-4 percentage-point gap between Foundayo labeled-dose 11.1% and Wegovy 14.9% is the best available approximation but is not a head-to-head trial result. A direct ATTAIN vs STEP randomized trial has not been published as of May 2026.

Side-effect profile: shared class effects

Because both drugs act on the same receptor, the side-effect profile overlaps heavily. Both share the GLP-1 receptor agonist class effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and (rarely) acute pancreatitis. Both labels carry the FDA boxed warning for risk of thyroid C-cell tumors based on rodent carcinogenicity data, and both contraindicate use in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Pooled adverse-event rates from the pivotal trials at the highest labeled doses:

• Nausea: ~32-38% on Foundayo across ATTAIN-1 dose arms (highest in the 36 mg arm); ~44% on Wegovy 2.4 mg in STEP-1^[1][4]. Most events are mild to moderate and cluster in the dose-escalation period for both drugs.
• Vomiting: ~14-23% on Foundayo dose arms; ~24% on Wegovy 2.4 mg.
• Diarrhea: ~17-26% on Foundayo dose arms; ~30% on Wegovy 2.4 mg.
• Constipation: ~15-23% on Foundayo dose arms; ~24% on Wegovy 2.4 mg.
• Discontinuation for adverse events: ATTAIN-1 reported dose-dependent discontinuation; STEP-1 reported 7.0% on Wegovy 2.4 mg vs 3.1% on placebo^[4].

One side-effect distinction is unique to Foundayo: a drug-interaction-driven dose cap. Section 7 of the Foundayo US Prescribing Information specifies that patients on strong CYP3A4 inhibitors must cap the Foundayo dose at 9 mg daily (not the 17.2 mg labeled max), because orforglipron exposure increases substantially when CYP3A4 is inhibited^[7]. Wegovy has no such CYP-mediated interaction because semaglutide is a peptide cleared by proteolysis, not by hepatic CYP metabolism. Patients on ketoconazole, itraconazole, clarithromycin, or other strong CYP3A4 inhibitors will hit a lower Foundayo dose ceiling than patients without those concomitant medications. For the deeper Foundayo-specific side-effect breakdown see the Foundayo side-effect evidence review.

Form factor and practical access

The single biggest non-clinical differentiator between Foundayo and Wegovy is the delivery route. Foundayo is the first oral GLP-1 ever FDA-approved for chronic weight management. Wegovy is a weekly subcutaneous injection delivered by prefilled pen. The practical consequences span travel, storage, needle anxiety, and family integration.

• Daily oral tablet vs weekly injection. Foundayo patients swallow one tablet daily at any time of day, with or without food, with no water restrictions per the FDA prescribing information^[7]. Wegovy patients inject subcutaneously once weekly at a self-selected day and time.
• Refrigeration vs room-temperature storage. Wegovy pens must be refrigerated between 36-46°F until first use, with a 28-day room-temperature tolerance once in use. Foundayo tablets are stored at room temperature with no cold chain. Travel, vacation, power outages, and dorm-room storage all favor Foundayo on a logistics axis.
• Needle anxiety. A non-trivial subset of patients who would benefit from a GLP-1 do not start one because of injection aversion. Foundayo removes that barrier entirely.
• Family integration. A daily tablet integrates into an existing morning or evening pill routine the way a weekly injection does not.

For the broader landscape of oral GLP-1 options including oral semaglutide (Rybelsus) and the practical differences between them, see the oral GLP-1 pills comparison.

Cardiovascular outcomes: SELECT vs emerging Foundayo data

Wegovy and Foundayo are at very different stages of the cardiovascular outcomes evidence base.

SELECT: the trial that gave Wegovy a CV indication

SELECT (Lincoff et al., NEJM 2023) randomized 17,604 adults aged 45+ with established cardiovascular disease and overweight or obesity but without diabetes to semaglutide 2.4 mg weekly or placebo, with a median follow-up of 39.8 months. The primary MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 6.5% of the semaglutide group vs 8.0% of placebo (HR 0.80, 95% CI 0.72-0.90, p<0.001). SELECT supported the 2024 FDA label expansion adding a cardiovascular indication to Wegovy^[6]. The Wegovy CV indication has practical coverage consequences: it has opened Medicare Part D coverage for Wegovy when prescribed for CV risk reduction in adults with established CV disease and obesity, routing around the statutory Medicare anti-obesity-drug exclusion.

ACHIEVE-CVOT: the Foundayo CV trial still enrolling

Eli Lilly is conducting the orforglipron cardiovascular outcomes trial under the ACHIEVE-CVOT program. As of May 2026 the trial is enrolling and has not reported. Until ACHIEVE-CVOT reports, Foundayo does not carry an FDA-approved cardiovascular indication and is not covered under Medicare Part D for cardiovascular risk reduction. Patients whose primary clinical concern is cardiovascular risk reduction in addition to weight loss currently have a stronger on-label case for Wegovy than for Foundayo. The ATTAIN-MAINTAIN trial (Aronne 2026) addressed the maintenance question for Foundayo^[3] but is not a CV outcomes trial.

Type 2 diabetes context

Wegovy is not FDA-approved for type 2 diabetes (its sister drug, Ozempic, carries the T2D indication for semaglutide). Foundayo is approved for chronic weight management in the obesity population, with the ATTAIN-2 trial (Horn et al., Lancet 2026) supporting the Foundayo profile in adults with T2D plus obesity^[2]. Patients with T2D have two main paths to consider:

• T2D plus obesity, want a pill: Foundayo. The ATTAIN-2 evidence base supports use in adults with T2D and obesity, and Foundayo delivers the oral-route differentiator from injectable peers.
• T2D plus obesity plus established CV disease, want maximum on-label coverage: Wegovy is on-label for the CV indication based on SELECT; the related sister drug Ozempic is on-label for the T2D + CV indication based on SUSTAIN-6. The prescriber may pick Wegovy or Ozempic depending on the relative weight of the weight-management vs glycemic-control axis.
• T2D without established CV disease, primary goal weight loss: Both Foundayo and Wegovy are reasonable on weight grounds. Choice often comes down to delivery preference and insurance coverage.

For the deeper semaglutide-vs-semaglutide indication comparison see the Wegovy vs Ozempic evidence review.

Cost framing: what actually drives the price gap

Cash-pay pricing and insurance coverage shift constantly, so this article describes the structural cost levers rather than fixing on dollar amounts that will be stale within months. The mechanism of cost difference between Foundayo and Wegovy follows three levers:

• Manufacturing economics. A small-molecule tablet has lower per-dose manufacturing and distribution cost than a peptide drug delivered in a single-use prefilled pen. Tablet production at scale is a mature, cheap process; peptide synthesis plus injection-pen assembly is more expensive at every step.
• Cold-chain logistics. Wegovy must move through a refrigerated supply chain from manufacturer to pharmacy and must be stored cold in the patient’s refrigerator until first use. Foundayo moves through room-temperature shipping and storage. Cold-chain logistics add cost at every node.
• Insurance-coverage path. Wegovy has the SELECT-supported CV indication that has opened Medicare Part D coverage for cardiovascular risk reduction in obesity + CV disease. Foundayo does not carry that indication yet. Commercial-plan coverage for either drug depends on the specific formulary, the prior-authorization requirements, and the chronic-weight-management benefit design of the plan.

Self-pay channels exist for both drugs. Check the manufacturer self-pay program (LillyDirect for Foundayo; NovoCare Pharmacy for Wegovy) and your insurance formulary tier for current pricing. Compounded semaglutide is no longer broadly available as a routine cash-pay workaround following the February 2025 FDA resolution of the semaglutide shortage; the regulatory window for routine compounding closed at that point.

Which to choose: a decision framework

Mapping the FDA labels, the trial data, the side-effect profile, and the access reality onto patient profiles produces a decision framework rather than a single answer. The right choice for any individual patient is made with a licensed prescriber who has reviewed the full FDA prescribing information for both drugs and the individual’s history.

• Maximum mean weight loss is the goal, willing to inject: Wegovy. STEP-1 reported about −14.9% mean body weight versus Foundayo’s labeled-dose ~11.1%.
• Established CV disease + obesity, no T2D: Wegovy. The SELECT-supported CV indication is exactly this population and opens Medicare Part D coverage under the CV indication.
• Needle aversion is the controlling factor: Foundayo. The only FDA-approved oral GLP-1 for weight management as of 2026. Lower mean ceiling, but a real medication beats no medication.
• Travel-heavy lifestyle or unreliable cold-chain storage: Foundayo. Room-temperature storage and a daily tablet integrate into an existing pill routine.
• On strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, certain protease inhibitors): Wegovy may be the cleaner choice. The Foundayo label caps the dose at 9 mg daily with strong CYP3A4 inhibitors per Section 7 of the PI, which constrains the achievable weight-loss ceiling^[7]. Wegovy has no CYP-mediated interaction.
• Currently on Wegovy 2.4 mg and wanting to switch to oral: A reasonable Foundayo trial with re-titration from 3 mg daily and a tolerability check at each step. Expect mean weight loss to plateau modestly lower than the Wegovy result.
• Currently on Foundayo 17.2 mg and wanting more weight loss: A reasonable Wegovy switch with re-titration from 0.25 mg weekly. Expect the higher Wegovy maintenance dose to push GI tolerability harder than Foundayo did.

For the broader three-way comparison that also includes Zepbound (tirzepatide), see the Foundayo vs Wegovy vs Zepbound three-drug head-to-head.

Bottom line

• Different molecules, same receptor. Wegovy is a peptide injection; Foundayo is a small-molecule oral tablet. Both target the GLP-1 receptor as monoagonists; neither is a dual-agonist like tirzepatide.
• Wegovy edges Foundayo on mean weight loss. STEP-1 reported about −14.9% on Wegovy 2.4 mg weekly; ATTAIN-1 reported approximately −11.1% on Foundayo 17.2 mg daily at the FDA-labeled max dose. The 3-4 point gap is a matched-population indirect comparison, not a head-to-head trial.
• Foundayo wins on form factor. Oral daily tablet, room-temperature storage, no refrigeration, no injection, no food or water restrictions.
• Cardiovascular evidence currently favors Wegovy. SELECT supported the 2024 Wegovy CV indication. Foundayo’s ACHIEVE-CVOT trial is enrolling but has not reported.
• Side-effect profile largely overlaps. Both carry the GLP-1 class GI effects and the FDA boxed warning for thyroid C-cell tumors. Foundayo has a unique strong-CYP3A4- inhibitor dose cap that Wegovy does not.
• Cost mechanism favors Foundayo. Oral small-molecule tablets manufactured at scale undercut peptide- injection cold-chain logistics on the cost side; insurance coverage depends on the specific plan and the cardiovascular-vs-weight-management indication routing.

Frequently asked questions

Related research

• Foundayo vs Wegovy vs Zepbound: 2026 head-to-head — extends this two-drug comparison to a three-way comparison including tirzepatide.
• What is orforglipron (Foundayo)? — the foundational explainer on the molecule, the maker, the mechanism, and the FDA approval.
• Foundayo FDA approval explainer — the April 1, 2026 FDA approval and the dose-ladder details from the label.
• Wegovy vs Ozempic evidence review — the same-molecule, different-FDA-indication comparison on the semaglutide side.
• Tirzepatide vs semaglutide head-to-head review — SURMOUNT-5 direct head-to-head data for the dual-agonist comparison.
• Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, and dose ladder.
• Foundayo side-effect evidence review — the deeper ATTAIN-1 adverse-event breakdown and the CYP3A4 dose-cap interaction.
• Foundayo drug profile — full label, dose ladder, side-effect rates, and provider availability.
• Wegovy drug profile — full label, dose ladder, side-effect rates, and provider availability.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Foundayo and Wegovy are prescription medications with boxed warnings and contraindications; every clinical decision involving either drug must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history. Every regulatory claim in this article is anchored to a primary source (DailyMed, the manufacturer prescribing information, or PubMed). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.